CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum

Schnell, O; Agarwal, A; Azizi, M; Ballwieser, D; Barnard-Kelly, K; Battelino, T; Ballwieser, D; Blüher, M; Bugianesi, E; Cebrian, A; Ceriello, A; Choudhary, P; Danne, T; Dayan, CM; Del Prato, S; Eckel, RH; Fioretto, P; Garvey, T; Green, JB; Heerspink, HJL; Holman, RR; Itzhak, B; Jacob, S; Jhund, PS; Ji, L; Judge, PK; Khunti, K; Korenjak, M; Krentz, AJ; Lambrinou, E; Libby, P; Mader, JK; Mann, JFE; Marx, N; Mathieu, C; McMurray, JJV; Müller-Wieland, D; Papanas, N; Patel, DC; Pfeiffer, AFH; Reger-Tan, S; Rodbard, HW; Rosano, GMC; Saboo, B; Sato, N; Solomon, SD; Standl, E; Tacke, F; Topsever, P; Wanner, C; Wharton, S; Young, V

doi:10.1186/s12933-026-03140-0

Type 2 & other diabetes

Cardiovascular Outcome Trial (CVOT) Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum

Cardiovasc DiabetolPublished 6 May 2026Conference report

Read the original article ↗PubMed

Cite

Methodological detailsvirtual congress, multidisciplinary

Virtual congress
Multidisciplinary

Main finding

As reported in the abstract

Report of the 11th CVOT Summit (November 20-21, 2025): recent outcome trials of emerging therapies across the cardiovascular-kidney-metabolic (CKM) continuum, incl. first head-to-head CVOT (SURPASS-CVOT), combination therapies, inflammation in CKM syndrome and policy developments
Trials summarized: finerenone + empagliflozin combination (CONFIDENCE), oral GLP-1 RA orforglipron (ATTAIN-1), aldosterone synthase inhibitor baxdrostat (BaxHTN)
Guideline and policy developments; advances in continuous glucose and ketone monitoring; emerging therapies incl. for metabolic liver disease and T1D

Reference

Authors: Schnell O, Agarwal A, Azizi M, Ballwieser D, Barnard-Kelly K, Battelino T, et al.
All 52 authors
Schnell O, Agarwal A, Azizi M, Ballwieser D, Barnard-Kelly K, Battelino T, Ballwieser D, Blüher M, Bugianesi E, Cebrian A, Ceriello A, Choudhary P, Danne T, Dayan CM, Del Prato S, Eckel RH, Fioretto P, Garvey T, Green JB, Heerspink HJL, Holman RR, Itzhak B, Jacob S, Jhund PS, Ji L, Judge PK, Khunti K, Korenjak M, Krentz AJ, Lambrinou E, Libby P, Mader JK, Mann JFE, Marx N, Mathieu C, McMurray JJV, Müller-Wieland D, Papanas N, Patel DC, Pfeiffer AFH, Reger-Tan S, Rodbard HW, Rosano GMC, Saboo B, Sato N, Solomon SD, Standl E, Tacke F, Topsever P, Wanner C, Wharton S, Young V
Journal: Cardiovascular Diabetology
Published: 6 May 2026
DOI: 10.1186/s12933-026-03140-0
PubMed: 42092956

Topic: Type 2 & other diabetes
Also indexed: Diabetes complications

Original publication

CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum. Cardiovasc Diabetol. Published 6 May 2026. doi:10.1186/s12933-026-03140-0

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →